CY1122283T1 - Συνδυασμος ενος αντισωματος cd30xcd16a με ενα ανταγωνιστικο αντισωμα αντι-pd-1 για θεραπεια - Google Patents
Συνδυασμος ενος αντισωματος cd30xcd16a με ενα ανταγωνιστικο αντισωμα αντι-pd-1 για θεραπειαInfo
- Publication number
- CY1122283T1 CY1122283T1 CY20191101115T CY191101115T CY1122283T1 CY 1122283 T1 CY1122283 T1 CY 1122283T1 CY 20191101115 T CY20191101115 T CY 20191101115T CY 191101115 T CY191101115 T CY 191101115T CY 1122283 T1 CY1122283 T1 CY 1122283T1
- Authority
- CY
- Cyprus
- Prior art keywords
- antibody
- therapy
- cd30xcd16a
- combination
- competitive
- Prior art date
Links
- 230000002860 competitive effect Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 208000017604 Hodgkin disease Diseases 0.000 abstract 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 abstract 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 abstract 1
- 101100334515 Homo sapiens FCGR3A gene Proteins 0.000 abstract 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 abstract 1
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15166303.6A EP3091031A1 (en) | 2015-05-04 | 2015-05-04 | Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor |
| EP16152650 | 2016-01-25 | ||
| PCT/EP2016/060113 WO2016177846A1 (en) | 2015-05-04 | 2016-05-04 | Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122283T1 true CY1122283T1 (el) | 2020-11-25 |
Family
ID=56026814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191101115T CY1122283T1 (el) | 2015-05-04 | 2019-10-25 | Συνδυασμος ενος αντισωματος cd30xcd16a με ενα ανταγωνιστικο αντισωμα αντι-pd-1 για θεραπεια |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11167029B2 (enExample) |
| EP (1) | EP3292153B1 (enExample) |
| JP (1) | JP6609784B2 (enExample) |
| CN (1) | CN107847587B (enExample) |
| AU (1) | AU2016257334B2 (enExample) |
| BR (1) | BR112017023579A2 (enExample) |
| CA (2) | CA3219372A1 (enExample) |
| CY (1) | CY1122283T1 (enExample) |
| DK (1) | DK3292153T3 (enExample) |
| ES (1) | ES2754557T3 (enExample) |
| HR (1) | HRP20191933T1 (enExample) |
| HU (1) | HUE045866T2 (enExample) |
| LT (1) | LT3292153T (enExample) |
| PL (1) | PL3292153T3 (enExample) |
| PT (1) | PT3292153T (enExample) |
| RS (1) | RS59489B1 (enExample) |
| RU (1) | RU2761352C2 (enExample) |
| SI (1) | SI3292153T1 (enExample) |
| SM (1) | SMT201900598T1 (enExample) |
| WO (1) | WO2016177846A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110461357A (zh) | 2017-02-28 | 2019-11-15 | 阿菲姆德股份有限公司 | 抗cd16a抗体与细胞因子的组合 |
| JP7115758B2 (ja) * | 2017-02-28 | 2022-08-09 | アッフィメッド・ゲー・エム・ベー・ハー | Ｃｄ１６ａ指向性ｎｋ細胞エンゲージメント用タンデムダイアボディ |
| CN109706163A (zh) * | 2017-10-26 | 2019-05-03 | 深圳新诺微环生物科技有限公司 | 微环dna表达连接人与动物靶细胞与效应细胞的桥接分子及其应用 |
| CN109706164A (zh) * | 2017-10-26 | 2019-05-03 | 深圳新诺微环生物科技有限公司 | 微环dna表达连接人和猴cd20与效应细胞抗原的桥接分子及其应用 |
| CA3090464A1 (en) * | 2018-03-14 | 2019-09-19 | Affimed Gmbh | Bispecific egfr/cd16 antigen-binding protein |
| MX2020010728A (es) | 2018-04-13 | 2020-11-06 | Affimed Gmbh | Constructos de fusion de anticuerpos que se acoplan a celulas nk. |
| KR20210052494A (ko) * | 2018-08-27 | 2021-05-10 | 아피메트 게엠베하 | 항체 구조물이 사전 로드된 동결 보존된 nk 세포 |
| CN109402168A (zh) * | 2018-10-30 | 2019-03-01 | 深圳新诺微环生物科技有限公司 | 微环dna表达连接her2阳性细胞与效应细胞的桥接分子及其应用 |
| AU2020292339A1 (en) * | 2019-06-11 | 2022-01-20 | Myeloid Therapeutics, Inc. | Macrophage specific engager compositions and methods of use thereof |
| WO2021130383A1 (en) * | 2019-12-27 | 2021-07-01 | Affimed Gmbh | Method for the production of bispecific fcyriii x cd30 antibody construct |
| US20240343811A1 (en) | 2021-06-29 | 2024-10-17 | Shandong Simcere Biopharmacutical Co., Ltd. | Cd16 antibody and use thereof |
| JP7503215B2 (ja) | 2021-10-08 | 2024-06-19 | ジェンマブ エー／エス | Ｃｄ３０及びｃｄ３に結合する抗体 |
| US20240424099A1 (en) * | 2021-11-04 | 2024-12-26 | Artiva Biotherapeutics, Inc. | Treatment of cancer with nk cells and multispecific engagers |
| WO2023080895A1 (en) * | 2021-11-04 | 2023-05-11 | Artiva Biotherapeutics, Inc. | Treatment of cancer with nk cells and multispecific engagers |
| CN116059348A (zh) * | 2022-09-16 | 2023-05-05 | 四川大学华西医院 | 基于nkg2d的细胞接合器分子在清除衰老细胞中的应用 |
| AU2023404602A1 (en) | 2022-11-29 | 2025-05-29 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Cldn18.2/4-1bb binding protein and medical use thereof |
| TW202506178A (zh) | 2023-04-05 | 2025-02-16 | 丹麥商珍美寶股份有限公司 | 包含與ｃｄ３０和ｃｄ３結合之抗體之醫藥組成物 |
| CN117442721B (zh) * | 2023-12-20 | 2024-03-15 | 苏州艾凯利元生物科技有限公司 | 一种包括nk细胞和nk细胞接合器分子的组合物 |
| CN118791616A (zh) * | 2024-09-14 | 2024-10-18 | 苏州为度生物技术有限公司天津分公司 | 一种抗人cd16工程抗体及应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0510790D0 (en) * | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| EP3130350A1 (en) * | 2005-06-08 | 2017-02-15 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| WO2016029073A2 (en) * | 2014-08-22 | 2016-02-25 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
-
2016
- 2016-05-04 HU HUE16723968A patent/HUE045866T2/hu unknown
- 2016-05-04 WO PCT/EP2016/060113 patent/WO2016177846A1/en not_active Ceased
- 2016-05-04 PT PT167239680T patent/PT3292153T/pt unknown
- 2016-05-04 AU AU2016257334A patent/AU2016257334B2/en active Active
- 2016-05-04 PL PL16723968T patent/PL3292153T3/pl unknown
- 2016-05-04 ES ES16723968T patent/ES2754557T3/es active Active
- 2016-05-04 DK DK16723968.0T patent/DK3292153T3/da active
- 2016-05-04 EP EP16723968.0A patent/EP3292153B1/en active Active
- 2016-05-04 SM SM20190598T patent/SMT201900598T1/it unknown
- 2016-05-04 CA CA3219372A patent/CA3219372A1/en active Pending
- 2016-05-04 HR HRP20191933TT patent/HRP20191933T1/hr unknown
- 2016-05-04 CA CA2983706A patent/CA2983706C/en active Active
- 2016-05-04 SI SI201630463T patent/SI3292153T1/sl unknown
- 2016-05-04 JP JP2017557405A patent/JP6609784B2/ja active Active
- 2016-05-04 RU RU2017137251A patent/RU2761352C2/ru active
- 2016-05-04 LT LT16723968T patent/LT3292153T/lt unknown
- 2016-05-04 CN CN201680026411.5A patent/CN107847587B/zh active Active
- 2016-05-04 RS RS20191372A patent/RS59489B1/sr unknown
- 2016-05-04 BR BR112017023579A patent/BR112017023579A2/pt active Search and Examination
-
2017
- 2017-10-19 US US15/788,177 patent/US11167029B2/en active Active
-
2019
- 2019-10-25 CY CY20191101115T patent/CY1122283T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SMT201900598T1 (it) | 2020-01-14 |
| RS59489B1 (sr) | 2019-12-31 |
| DK3292153T3 (da) | 2019-10-21 |
| AU2016257334B2 (en) | 2021-08-12 |
| US11167029B2 (en) | 2021-11-09 |
| CN107847587B (zh) | 2020-10-09 |
| CA2983706C (en) | 2024-01-02 |
| PT3292153T (pt) | 2019-11-05 |
| RU2761352C2 (ru) | 2021-12-07 |
| LT3292153T (lt) | 2019-11-11 |
| EP3292153B1 (en) | 2019-07-31 |
| RU2017137251A3 (enExample) | 2019-10-10 |
| CA2983706A1 (en) | 2016-11-10 |
| ES2754557T3 (es) | 2020-04-20 |
| JP2018514576A (ja) | 2018-06-07 |
| US20180085456A1 (en) | 2018-03-29 |
| HUE045866T2 (hu) | 2020-01-28 |
| JP6609784B2 (ja) | 2019-11-27 |
| HRP20191933T1 (hr) | 2020-01-10 |
| RU2017137251A (ru) | 2019-06-04 |
| PL3292153T3 (pl) | 2020-02-28 |
| AU2016257334A1 (en) | 2017-11-09 |
| CA3219372A1 (en) | 2016-11-10 |
| CN107847587A (zh) | 2018-03-27 |
| SI3292153T1 (sl) | 2020-01-31 |
| WO2016177846A1 (en) | 2016-11-10 |
| HK1253022A1 (zh) | 2019-06-06 |
| BR112017023579A2 (pt) | 2018-07-24 |
| EP3292153A1 (en) | 2018-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122283T1 (el) | Συνδυασμος ενος αντισωματος cd30xcd16a με ενα ανταγωνιστικο αντισωμα αντι-pd-1 για θεραπεια | |
| CY1126855T1 (el) | Ενωσεις κυκλικων δινουκλεοτιδιων για τη θεραπευτικη αγωγη καρκινου | |
| CY1123858T1 (el) | Συζευγματα αντισωματος enanti-cmet δραστικης ουσιας και μεθοδοι για τη χρηση αυτων | |
| CY1126115T1 (el) | Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων | |
| MX387283B (es) | Tratamiento del cancer con tg02. | |
| CY1122510T1 (el) | Μορια αντισωματος σε lag-3 και χρησεις αυτων | |
| CL2019001874A1 (es) | Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos. | |
| CY1122642T1 (el) | Αντι-β7-η1 και anti-ctla-4 αντισωματα για τη θεραπευτικη αγωγη μη μικροκυτταρικου πνευμονικου καρκινου | |
| MX2018008346A (es) | Terapia de combinación de virus oncológico e inhibidor de punto de control. | |
| BR112018077492A2 (pt) | métodos de tratamento de câncer de ovário | |
| EA201790180A1 (ru) | Способы и терапевтические комбинации для лечения опухолей | |
| EA201791736A1 (ru) | Комбинированная терапия для лечения рака | |
| BR112015020911A2 (pt) | anticorpo, uso de uma combinação e método de tratamento | |
| BR112019002331A2 (pt) | anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos | |
| DK3740504T3 (da) | CD70 kombinationsterapi | |
| MY178726A (en) | Combination therapy of an afucosylated cd20 antibody with a btk inhibitor | |
| EA202191556A1 (ru) | Комбинированная терапия радиоиммуноконъюгатами и ингибиторами контрольных точек | |
| MX2020006297A (es) | Variantes de cd19. | |
| EA201991818A1 (ru) | Лечение рака | |
| MY188849A (en) | Combination therapy of an anti cd20 antibody with a bcl-2 inhibitor and a mdm2 inhibitor | |
| MX2018010709A (es) | Terapia del cancer con un virus oncolitico combinado con un inhibidor de punto de control. | |
| CY1124949T1 (el) | Αντισωμα | |
| MX2022007955A (es) | Regimenes de dosificacion de erdafitinib. | |
| CY1124759T1 (el) | Μεθοδοι για τη θεραπεια της οξειας νεφρικης βλαβης | |
| CY1123019T1 (el) | Σπειροκυκλικες ενωσεις |